{"groups":[{"description":"Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.","id":"FG000","title":"Asciminib (Imatinib Stratum)"},{"description":"Patients took ascimimib 80 mg QD under fasting conditions on ongoing basis.","id":"FG001","title":"Asciminib (2nd Generation TKI Stratum)"},{"description":"Patients took on ongoing basis the Investigator selected TKI (imatinib)","id":"FG002","title":"Investigator Selected TKI (Imatinib Stratum)"},{"description":"Patients took on ongoing basis the 2G investigator selected TKIs (nilotinib, or dasatinib, or bosutinib)","id":"FG003","title":"Investigator Selected TKI (2nd Generation TKI Stratum"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"21"},{"groupId":"FG003","numSubjects":"10"}],"type":"Unsatisfactory therapeutic effect"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"10"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}],"type":"Protocol Deviation"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}],"type":"Subject Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Pregnancy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"}],"type":"Participants not treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"101"},{"groupId":"FG001","numSubjects":"100"},{"groupId":"FG002","numSubjects":"102"},{"groupId":"FG003","numSubjects":"102"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"}],"type":"Participants Not Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"100"},{"groupId":"FG001","numSubjects":"100"},{"groupId":"FG002","numSubjects":"100"},{"groupId":"FG003","numSubjects":"101"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"85"},{"groupId":"FG001","numSubjects":"88"},{"groupId":"FG002","numSubjects":"63"},{"groupId":"FG003","numSubjects":"77"}],"comment":"Participants for whom treatment is ongoing at the time of Data Cut-Off (DOC)","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"39"},{"groupId":"FG003","numSubjects":"25"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Prior to randomization, the Investigator, in consultation with the participant, considering current treatment paradigm and participant characteristics - and comorbidities, made a selection of imatinib or 2G TKI (nilotinib, dasatinib, or bosutinib) to be used if the participant is randomized to the comparator arm.\n\nThe enrolment into the strata of imatinib versus 2G TKI was managed by IRT to be approximately 50% versus 50%.","recruitmentDetails":"All trial participants randomized in a 1:1 ratio between asciminib and investigator selected TKI (imatinib 400 mg QD, nilotinib 300 mg BD, dasatinib 100 mg QD or bosutinib 400 mg QD)."}